GlassScriptPhysician profile
Todd S Anhalt
NPI 1255316626
$11,563.86
in general payments reported to CMS, 2019-2025
28 companies · $2,367 in 2025
The $2,367 reported for 2025 was more than what 80% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $919 · 2020: $902 · 2021: $1,536 · 2022: $1,592 · 2023: $1,969 · 2024: $2,279 · 2025: $2,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,401 · Education: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,400.58 |
| Education | $213.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,178.19 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Genzyme Corporation | $1,313.11 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,197.44 | 2019-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $880.11 | 2019-2025 | Adbry |
| Janssen Biotech, INC. | $744.32 | 2019-2024 | Tremfya, Simponi, Remicade |
| Incyte Corporation | $587.55 | 2021-2025 | Opzelura, Opzelura |
| Sun Pharmaceutical Industries INC. | $496.62 | 2019-2025 | Absorica Ld, Winlevi |
| Pfizer INC. | $495.38 | 2020-2025 | |
| Galderma Laboratories, L.P. | $425.77 | 2019-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $408.60 | 2021-2024 | Sotyktu |
| Ucb, INC. | $341.46 | 2019-2025 | Bimzelx |
| Amgen INC. | $329.67 | 2022-2025 | Otezla, Otezla |
| Lilly USA, LLC | $303.06 | 2019-2025 | Taltz, Ebglyss |
| Epi Health, LLC | $275.08 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $222.11 | 2021-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $220.66 | 2019-2025 | Jublia, Arazlo, Cabtreo |
| Novartis Pharmaceuticals Corporation | $187.61 | 2019-2025 | |
| Dermira, INC. | $174.85 | 2019-2021 | |
| Arcutis Biotherapeutics, INC. | $160.01 | 2023-2025 | Zoryve |
| Janssen Scientific Affairs, LLC | $148.07 | 2021 | |
| Organogenesis INC. | $106.14 | 2021-2023 | Puraply |
| Organon LLC | $100.20 | 2025 | Vtama |
| Almirall LLC | $91.68 | 2020-2022 | |
| Genentech USA, INC. | $71.33 | 2019-2020 | |
| Vyne Pharmaceuticals INC. | $35.85 | 2021 | |
| Dermavant Sciences, INC. | $30.32 | 2024 | Vtama |
| Verrica Pharmaceuticals INC. | $22.76 | 2025 | Ycanth |
| Tactile Systems Technology INC | $15.91 | 2025 | Flexitouch Plus, Nimbl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Anhalt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.